- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02545712
Safe Excipient Exposure in Neonates and Small ChildreN (SEEN)
Safe Excipient Exposure in Neonates and Small ChildreN - a Retrospective, Descriptive Study Off the Amount of Ethanol, Propylene Glycol, Benzyl Alcohol, Parabens, Acesulfam k, Aspartame, Glycerol, Sorbitol and Polysorbate-80 Exposed to Pediatric Patients
Study Overview
Status
Conditions
Intervention / Treatment
- Other: Exposure to ethanol
- Other: Exposure to propylene glycol
- Other: Exposure to benzyl alcohol
- Other: Exposure to acesulfam potassium
- Other: Exposure to aspartame
- Other: Exposure to glycerol
- Other: Exposure to sorbitol
- Other: Exposure to methyl-p-hydroxybenzoate
- Other: Exposure to propanyl-p-hydroxybenzoate
- Other: Exposure to polysorbate-80
Detailed Description
Studies have previously examined whether or not neonatal nor pediatric patients are exposed to excipients and what excipients they are possibly exposed to. They have shown that practically all neonatal patients receive one or more drug containing an excipient, known to be harmful. This observational study will look at both registered drugs and extemporaneous pharmaceuticals as possible sources of excipients. Based on information provided by the manufacturer (ex. the index-list), the investigator will calculate the amounts of excipients administered to the patient a week after hospitalisation. The investigator will calculate the blood alcohol content when the neonatal patient are exposed to ethanol and/or propylene glycol.
By grouping the patients according to age and subgrouping according to diagnosis/affected organ system and compare the amount of excipient exposure in each group, the study aims at identifying the most vulnerable neonatal and/or pediatric patients in terms of the amount and identity of excipients accumulated in the patient.
The study will use a descriptive, parametric statistic analysis to identify
- an average exposure rate (concentration i mg/l or amount in mg) of each of the listed excipients
- how much the average patient in each age-group is exposed to each excipient
- how much the average patient in each "affected organ system"-subgroup is exposed to each excipient
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Neonatal patients and pediatric patients (≤ 5 years) who, at one point, have been/are being treated at the "Neonatalklinikken" (units 5021, 5023, 5024) or "BørneUngeklinikken" (units 5061, 5062, 5054, 4144) of Rigshospitalet, Denmark. To be included in the study, the patients must receive
- 2 or more different drugs if < 28 days old
- 3 or more different drugs if 28 day ≤ 5 years old
Description
Inclusion Criteria:
- if < 28 days: must receive 2 or more prescriptions a day
- if 28 days ≤ 5 years: must receive 3 or more prescriptions a day
- must have been/be submitted and treated at the neonatal department (units 5021, 5023, 5024) or pediatric department (units 5061, 5062, 5054, 4144) of Rigshospitalet
Exclusion Criteria:
- no up-dated weight is listed
- > 5 years old
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Neonatal patients
Receiving 2 or more drugs at one day during their hospitalisation.
For each drug, it is listed whether it is an extemporaneous, registered, the preparation, dosis, amount, interval, formulation and route of administration.
It is noted if the drug contains ethanol, propylene glycol, benzyl alcohol, methyl-p-hydroxybenzoate, propanyl-p-hydroxybenzoate, acesulfam potassium, aspartame, glycerin and/or sorbitol.
|
The drug source(s) and amount administered daily are noted.
Other Names:
The drug source(s) and amount administered daily are noted.
The drug source(s) and amount administered daily are noted.
The drug source(s) and amount administered daily are noted.
Other Names:
The drug source(s) and amount administered daily are noted.
The drug source(s) and amount administered daily are noted.
Other Names:
The drug source(s) and amount administered daily are noted.
The drug source(s) and amount administered daily are noted.
Other Names:
The drug source(s) and amount administered daily are noted.
Other Names:
The drug source(s) and amount administered daily are noted.
|
Pediatric patients (28 days ≤ 5 years)
Receiving 3 or more drugs at one day during their hospitalisation.
For each drug, it is listed whether it is an extemporaneous, registered, the preparation, dosis, amount, interval, formulation and route of administration.
It is noted if the drug contains ethanol, propylene glycol, benzyl alcohol, methyl-p-hydroxybenzoate, propanyl-p-hydroxybenzoate, acesulfam potassium, aspartame, glycerin and/or sorbitol.
|
The drug source(s) and amount administered daily are noted.
Other Names:
The drug source(s) and amount administered daily are noted.
The drug source(s) and amount administered daily are noted.
The drug source(s) and amount administered daily are noted.
Other Names:
The drug source(s) and amount administered daily are noted.
The drug source(s) and amount administered daily are noted.
Other Names:
The drug source(s) and amount administered daily are noted.
The drug source(s) and amount administered daily are noted.
Other Names:
The drug source(s) and amount administered daily are noted.
Other Names:
The drug source(s) and amount administered daily are noted.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood alcohol content measured in per mille (grams of ethanol and propylene glycol pr. kilograms of blood) in the patient
Time Frame: Single day
|
Both concentrations of ethanol and propylene glycol are included in the calculations.
with propylene glycol 1/3 as intoxicating as ethanol.
|
Single day
|
Concentration (mg/kg/day) of benzyl alcohol in the patient
Time Frame: Single day
|
Single day
|
|
Concentration (mg/kg/day) of acesulfam potassium in the patient
Time Frame: Single day
|
Single day
|
|
Concentration (mg/kg/day) of aspartame in the patient
Time Frame: Single day
|
Single day
|
|
Concentration (mg/kg/day) of glycerin in the patient
Time Frame: Single day
|
Single day
|
|
Concentration (mg/kg/day) of sorbitol in the patient
Time Frame: Single day
|
Single day
|
|
Concentration (mg/l) of methyl-p-hydroxybenzoate in the patient
Time Frame: Single day
|
Single day
|
|
Concentration (mg/kg/day) of propyl-p-hydroxybenzoate in the patient
Time Frame: Single day
|
Single day
|
|
Concentration (mg/kg/day) of polysorbate-80 in the patient
Time Frame: Single day
|
Single day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identification of patient group (according to age-interval) most vulnerable to excipient exposure (measured in number of excipients)
Time Frame: During the participants hospitalization, an expected average of 2 months
|
The excipients (ethanol, propylene glycol, benzyl alcohol, methyl-p-hydroxybenzoate, propyl-p-hydroxybenzoate, acesulfam potassium, aspartame, glycerol, polysorbate-80 and sorbitol) will be ranked according to which excipient is most often present in the medicine administered to the patients.
|
During the participants hospitalization, an expected average of 2 months
|
Identification of patient group (according to age-interval) most vulnerable to excipient exposure (amounts of each excipient measured in (mg/l))
Time Frame: During the participants hospitalization, an expected average of 2 months
|
The excipients (ethanol, propylene glycol, benzyl alcohol, methyl-p-hydroxybenzoate, propyl-p-hydroxybenzoate, acesulfam potassium, aspartame, glycerol, polysorbate-80 and sorbitol) will be ranked according to which excipient is most often present in the medicine administered to the patients.
|
During the participants hospitalization, an expected average of 2 months
|
Identification of patient group (according to affected organ system) most vulnerable to excipient exposure (measured in number of excipients)
Time Frame: During the participants hospitalization, an expected average of 2 months
|
The excipients (ethanol, propylene glycol, benzyl alcohol, methyl-p-hydroxybenzoate, propyl-p-hydroxybenzoate, acesulfam potassium, aspartame, glycerol, polysorbate-80 and sorbitol) will be ranked according to which excipient is most often present in the medicine administered to the patients.
|
During the participants hospitalization, an expected average of 2 months
|
Identification of patient group (according to affected organ system) most vulnerable to excipient exposure (amounts of each excipient measured in (mg/l))
Time Frame: During the participants hospitalization, an expected average of 2 months
|
The excipients (ethanol, propylene glycol, benzyl alcohol, methyl-p-hydroxybenzoate, propyl-p-hydroxybenzoate, acesulfam potassium, aspartame, glycerol, polysorbate-80 and sorbitol) will be ranked according to which excipient is most often present in the medicine administered to the patients.
|
During the participants hospitalization, an expected average of 2 months
|
Identification of number of patient exposed to ethanol levels above tolerance levels proposed by international medicines agencies like EMA and FDA
Time Frame: Single day
|
Comparison of each patient daily exposure rate of ethanol to daily tolerance limit
|
Single day
|
Identification of number of patient exposed to propylene glycol levels above tolerance levels proposed by international medicines agencies like EMA and FDA
Time Frame: Single day
|
Comparison of each patient daily exposure rate of proplyene glycol to daily tolerance limit
|
Single day
|
Identification of number of patient exposed to benzyl alcohol levels above tolerance levels proposed by international medicines agencies like EMA and FDA
Time Frame: Single day
|
Comparison of each patient daily exposure rate of benzyl alcohol to daily tolerance limit
|
Single day
|
Identification of number of patient exposed to methyl-p-hydroxy-benzoate levels above tolerance levels proposed by international medicines agencies like EMA and FDA
Time Frame: Single day
|
Comparison of each patient daily exposure rate of methyl-p-hydroxy-benzoate to daily tolerance limit
|
Single day
|
Identification of number of patient exposed to propyl-p-hydroxy-benzoate levels above tolerance levels proposed by international medicines agencies like EMA and FDA
Time Frame: Single day
|
Comparison of each patient daily exposure rate of propyl-p-hydroxy-benzoate to daily tolerance limit
|
Single day
|
Identification of number of patient exposed to sodium-propyl-p-hydroxy-benzoate levels above tolerance levels proposed by international medicines agencies like EMA and FDA
Time Frame: Single day
|
Comparison of each patient daily exposure rate of sodium-propyl-p-hydroxy-benzoate to daily tolerance limit
|
Single day
|
Identification of number of patient exposed to sodium-methyl-p-hydroxy-benzoate levels above tolerance levels proposed by international medicines agencies like EMA and FDA
Time Frame: Single day
|
Comparison of each patient daily exposure rate of sodium-methyl-p-hydroxy-benzoate to daily tolerance limit
|
Single day
|
Identification of number of patient exposed to acesulfame potassium levels above tolerance levels proposed by international medicines agencies like EMA and FDA
Time Frame: Single day
|
Comparison of each patient daily exposure rate of acesulfame potassium to daily tolerance limit
|
Single day
|
Identification of number of patient exposed to aspartame levels above tolerance levels proposed by international medicines agencies like EMA and FDA
Time Frame: Single day
|
Comparison of each patient daily exposure rate of aspartame to daily tolerance limit
|
Single day
|
Identification of number of patient exposed to glycerol levels above tolerance levels proposed by international medicines agencies like EMA and FDA
Time Frame: Single day
|
Comparison of each patient daily exposure rate of glycerol to daily tolerance limit
|
Single day
|
Identification of number of patient exposed to sorbitol levels above tolerance levels proposed by international medicines agencies like EMA and FDA
Time Frame: Single day
|
Comparison of each patient daily exposure rate of sorbitol to daily tolerance limit
|
Single day
|
Identification of number of patient exposed to polysorbate-80 levels above tolerance levels proposed by international medicines agencies like EMA and FDA
Time Frame: Single day
|
Comparison of each patient daily exposure rate of polysorbate-80 to daily tolerance limit
|
Single day
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kristine Svinning Valeur, MS, Bispebjerg Frederiksberg Hospital
Publications and helpful links
General Publications
- Nellis G, Metsvaht T, Varendi H, Toompere K, Lass J, Mesek I, Nunn AJ, Turner MA, Lutsar I; ESNEE consortium. Potentially harmful excipients in neonatal medicines: a pan-European observational study. Arch Dis Child. 2015 Jul;100(7):694-9. doi: 10.1136/archdischild-2014-307793. Epub 2015 Apr 8.
- Souza A Jr, Santos D, Fonseca S, Medeiros M, Batista L, Turner M, Coelho H. Toxic excipients in medications for neonates in Brazil. Eur J Pediatr. 2014 Jul;173(7):935-45. doi: 10.1007/s00431-014-2272-z. Epub 2014 Feb 6.
- Marek E, Kraft WK. Ethanol pharmacokinetics in neonates and infants. Curr Ther Res Clin Exp. 2014 Oct 22;76:90-7. doi: 10.1016/j.curtheres.2014.09.002. eCollection 2014 Dec.
- Nguyen KA, Claris O, Kassai B. Unlicensed and off-label drug use in a neonatal unit in France. Acta Paediatr. 2011 Apr;100(4):615-7. doi: 10.1111/j.1651-2227.2010.02103.x. Epub 2010 Dec 17. No abstract available.
- Jacqz-Aigrain E. Drug policy in Europe Research and funding in neonates: current challenges, future perspectives, new opportunities. Early Hum Dev. 2011 Mar;87 Suppl 1:S27-30. doi: 10.1016/j.earlhumdev.2011.01.007. Epub 2011 Jan 26.
- Allegaert K. Neonates need tailored drug formulations. World J Clin Pediatr. 2013 Feb 8;2(1):1-5. doi: 10.5409/wjcp.v2.i1.1. eCollection 2013 Feb 8.
- Bellis JR, Kirkham JJ, Thiesen S, Conroy EJ, Bracken LE, Mannix HL, Bird KA, Duncan JC, Peak M, Turner MA, Smyth RL, Nunn AJ, Pirmohamed M. Adverse drug reactions and off-label and unlicensed medicines in children: a nested case-control study of inpatients in a pediatric hospital. BMC Med. 2013 Nov 7;11:238. doi: 10.1186/1741-7015-11-238.
- Nahata MC. Safety of "inert" additives or excipients in paediatric medicines. Arch Dis Child Fetal Neonatal Ed. 2009 Nov;94(6):F392-3. doi: 10.1136/adc.2009.160192. No abstract available.
- Whittaker A, Currie AE, Turner MA, Field DJ, Mulla H, Pandya HC. Toxic additives in medication for preterm infants. Arch Dis Child Fetal Neonatal Ed. 2009 Jul;94(4):F236-40. doi: 10.1136/adc.2008.146035. Epub 2009 Jan 21.
- Saiyed MM, Lalwani T, Rana D. Is off-label use a risk factor for adverse drug reactions in pediatric patients? A prospective study in an Indian tertiary care hospital. Int J Risk Saf Med. 2015;27(1):45-53. doi: 10.3233/JRS-150642.
- Collison KS, Makhoul NJ, Zaidi MZ, Al-Rabiah R, Inglis A, Andres BL, Ubungen R, Shoukri M, Al-Mohanna FA. Interactive effects of neonatal exposure to monosodium glutamate and aspartame on glucose homeostasis. Nutr Metab (Lond). 2012 Jun 14;9(1):58. doi: 10.1186/1743-7075-9-58.
- Ornoy A, Ergaz Z. Alcohol abuse in pregnant women: effects on the fetus and newborn, mode of action and maternal treatment. Int J Environ Res Public Health. 2010 Feb;7(2):364-79. doi: 10.3390/ijerph7020364. Epub 2010 Jan 27.
- Lass J, Kaar R, Jogi K, Varendi H, Metsvaht T, Lutsar I. Drug utilisation pattern and off-label use of medicines in Estonian neonatal units. Eur J Clin Pharmacol. 2011 Dec;67(12):1263-71. doi: 10.1007/s00228-011-1072-x. Epub 2011 Jun 11.
- Fister P, Urh S, Karner A, Krzan M, Paro-Panjan D. The prevalence and pattern of pharmaceutical and excipient exposure in a neonatal unit in Slovenia. J Matern Fetal Neonatal Med. 2015;28(17):2053-61. doi: 10.3109/14767058.2014.976549. Epub 2015 Sep 4.
- Valeur KS, Hertel SA, Lundstrom KE, Holst H. Safe excipient exposure in neonates and small children - protocol for the SEEN project. Dan Med J. 2017 Feb;64(2):A5324.
Helpful Links
- European Medical Agensy. Questions and Answers on Ethanol in the context of the 5 revision of the guideline on 'Excipients in the label and 6 package leaflet of medicinal products for human use' [accessed September 3rd 2015]
- Isaac R, Khan I, Langley C. Ethanol intake of paediatric intensive care patients. Arch Dis Child 2013;98:e1 doi:10.1136/archdischild-2013-303935a.21
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Anti-Infective Agents, Local
- Anti-Infective Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Gastrointestinal Agents
- Protective Agents
- Anesthetics, Local
- Cathartics
- Cryoprotective Agents
- Ethanol
- Sorbitol
- Glycerol
- Benzyl Alcohol
Other Study ID Numbers
- BBH-KSV-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediatric
-
National Institute of Allergy and Infectious Diseases...Clinical Trials in Organ Transplantation in ChildrenCompletedPediatric Heart Transplantation | Pediatric Heart Transplant Recipients | Pediatric Cardiac TransplantationUnited States
-
Samsung Medical CenterMinistry of Health, Republic of KoreaRecruitingRelapsed Pediatric AML | Refractory Pediatric AML | Relapsed Pediatric Solid Tumor | Refractory Pediatric Solid TumorKorea, Republic of
-
University Hospital, Strasbourg, FranceTerminatedPediatric Lung Ultrasound | Pediatric Chest Radiography | Pediatric Lung DiagnosisFrance
-
University of BirminghamCompletedCancer | Pediatric ALL | Pediatric Solid Tumor | Pediatric AMLUnited Kingdom, Australia, Netherlands
-
TC Erciyes UniversityCompletedPediatric Cancer | Pediatric Brain Tumor | Pediatric Solid TumorTurkey
-
National Institute of Allergy and Infectious Diseases...National Heart, Lung, and Blood Institute (NHLBI)TerminatedPediatric Heart Transplantation | Pediatric Heart Transplant RecipientsUnited States, Canada
-
Hospital Moinhos de VentoNot yet recruitingAdolescent | Telemedicine | Critical Care | Pediatric | Intensive Care Units, Pediatric
-
Samsung Medical CenterMinistry of Health, Republic of KoreaNot yet recruitingRelapsed Pediatric Solid Tumor | Refractory Pediatric Solid TumorKorea, Republic of
-
University of CalgaryCanadian Institutes of Health Research (CIHR); Alberta Children's Hospital; Stollery... and other collaboratorsNot yet recruitingPediatric Cancer | Pediatric Hematology
-
National Taiwan University HospitalUnknownPalliative Care | Pediatric Cancer | Nursing Caries | Oncology | Pediatric PopulationTaiwan
Clinical Trials on Exposure to ethanol
-
University of PennsylvaniaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedObesity | Weight Gain | Food PreferencesUnited States
-
AlyatecCompletedAllergic Rhinitis | Rhinoconjunctivitis | Allergy to PollenFrance
-
University of BaselCompletedMuscle Strength | Endurance Performance | Reaction TimeSwitzerland
-
University of PennsylvaniaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
JAMK University Of Applied SciencesCompletedPhysiological Recovery | Psychological Recovery | Restorative ExperiencesFinland
-
Stanford UniversityHarvard Pilgrim Health CareCompletedObesity | Dietary Habits | Weight Gain | Weight PrejudiceUnited States
-
Fraunhofer-Institute of Toxicology and Experimental...RecruitingHealthy | Chronic Obstructive Pulmonary DiseaseGermany
-
University of North Carolina, Chapel HillDuke University; Stanford UniversityNot yet recruiting
-
ART Fertility Clinics LLCRecruitingInfertilityUnited Arab Emirates
-
University Hospital, MontpellierAix Marseille Université; LBM- Nanosecurity platform - CEA Grenoble; LR2N - Nanosecurity...CompletedRespiratory Function